### Live Learner Notification

#### **Med Learning GroupIC-ONC - Combination Treatment Options, Biomarkers and Immune-related Adverse Event Occurrence and Management During the COVID-19 Pandemic, Track 4: Hepatocellular Carcinoma**

**June 15, 2021**

**Online

Acknowledgement of Financial Commercial Support**

Bristol Myers Squibb

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 **Pharmacists and Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

UAN(s): JA4008163-9999-21-117-L04-P / JA4008163-9999-21-117-L04-T

**NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.**

###### Objectives - After Attending This Program You Should Be Able To

1. Review mechanisms of action and clinical profiles of immunotherapies used alone or in combination across lines of therapy for the treatment of HCC.
2. Recognize and manage side effects and toxicities associated with available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of RCC.
3. Discuss established and potential prognostic and predictive immune- and non-immune-related biomarkers for HCC and their impact on patient management strategies.
4. Summarize current recommendations and emerging evidence regarding the use of immunotherapies for patients with HCC during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine.
5. Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with RCC and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5).

All individuals in a position to control the content of CE are listed below:

|  |  |
| --- | --- |
| **Name** | **Relationship: Commercial Interest** |
| Matthew Frese | NA |
| Christina Gallo | NA |
| Robert G. Gish | Grants/Research Support: Gilead; Consultant and/or Advisor: Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, Viking Therapeutics; Current Activity with Scientific or Clinical Advisory Boards: Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, HepQuant, Intercept, Janssen; Clinical Trials Alliance: Topography Health; Advisory Board: Prodigy; Advisory Consultant: Biocollections, Fujifilm/Wako, Quest; Data Safety Monitoring Board: Arrowhead; Consulting Confidentiality Agreements: Abbvie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals Inc, Arrowhead, Arterys Inc Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Assoc, Dova Pharmaceuticals, DRG Abacus, DURECT Corporation, Dynavax, Echosens, Eiger, Enyo, Exelixis, Forty-Seven Inc, Fujifilm Wako Diagnostics, Gilead, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen/J&J, KannaLife, Laboratory for Advanced Medicine, Labyrinth Holdings, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, ProdigY Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi Inc, Spring Bank, Trimaran; Speakers Bureau: AbbVie, Bayer, BMS, Eisai, Gilead Sciences Inc., Intercept, and Salix; Minor Stock Shareholder: RiboSciences, CoCrystal; Stock Options: Eiger, Genlantis, HepQuant, AngioCrine; Expert Testimony for Pharma (Intellectual Property): Janssen USP Pharma |
| Debra Gordon | NA |
| Brianna Hanson | NA |
| Melissa A. Johnson | NA |
| Scott McGee-Plys | NA |
| Jessica McMullen | NA |
| Lauren Welch | NA |

**How to Get Your Certificate**

1. Go to <http://mlg.cmecertificateonline.com>

#### Click on**“6.15.21 IC-ONC - Track 4: Hepatocellular Carcinoma**” link.

1. Evaluate the meeting, click the provided link to open your credit certificate.
2. Print/save all pages of your certificate for your records.

Questions? Email Certificate@AmedcoEmail.com